The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the […]
Teva Pharmaceuticals
Amazon, Onica to support digital health for Teva’s Digihaler
Teva Respiratory (NYSE:TEVA) announced that it is collaborating with Amazon Web Services (AWS) and Onica to build and host its digital health platform. The Teva Pharmaceuticals affiliate’s digital health platform is a cloud-based backend data system designed to support its FDA-approved Digihaler portfolio of breath-actuated digital inhalers and its companion mobile app that tracks inhaler events […]
Teva launches 2 digital inhalers in U.S.
Teva Respiratory (NYSE:TEVA) announced that it launched its AirDuo Digihaler and ArmonAir Digihaler digital inhalers in the U.S. The U.S. affiliate of Teva Pharmaceutical Industries launched both digital inhalers as treatments for asthma. The AirDuo Digihaler is a prescription inhalation powder for controlling symptoms of asthma and preventing symptoms such as wheezing in people 12 years […]
Teva launches connected inhaler for asthma, COPD
Teva (NYSE:TEVA) announced today that it has launched a Bluetooth-enabled version of its ProAir albuterol sulfate rescue inhaler. The ProAir Digihaler’s sensors connect to a companion mobile app to provide inhaler-use information to healthcare providers. The new inhaler is available by prescription to U.S. patients age 4 and older, according to the Tel Aviv, Israel-based company. […]
Teva launches generic EpiPen Jr.
Teva (NYSE:TEVA) today announced that its FDA-approved generic EpiPen Jr. auto-injector is available in the U.S. The device wholesales to most retail pharmacies in packs of two for $300, or $150 per pen. Teva’s product is less than half the cost of Mylan’s non-generic EpiPen Jr., which lists at $643.89 per two-pack at Drugs.com. ”We’re […]
Teva wins FDA approval for AirDuo Digihaler for asthma
Teva (NYSE:TEVA) yesterday said that it received FDA approval for its AirDuo Digihaler Inhalation Powder. The Israel-based company’s AirDuo Digihaler is a combination therapy digital inhaler with built-in sensors that can connect to a smartphone application, indicated to treat asthma in people 12 years and older.. It delivers a multi-dose dry powder of 113mcg of fluticasone […]
Teva launches generic for Pfizer’s Flector pain patch
Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch. Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions. Pfizer’s Flector patch garnered annual sales of $123 million in the U.S. as of Dec. 2018, according […]
Teva aims for 25% of U.S. EpiPen market by 2020
Teva (NYSE:TEVA) expects its generic EpiPen auto-injector to claim 25% of the U.S. market by the end of this year, according to a report from Seeking Alpha. For years, Mylan‘s (NSDQ:MYL) brand-name emergency allergy device has dominated the markets. But the company faced widespread criticism in 2016 when reports revealed that Mylan hiked the price of the […]
FDA approves Teva’s digital COPD, asthma inhaler
Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic obstructive pulmonary disease. The company’s device features built-in sensors that can measure inspiratory flow and detect when the inhaler is used. After the […]
Teva launches generic EpiPen at the same price as existing device
Teva (NYSE:TEVA) this week launched its generic version of Mylan‘s (NSDQ:MYL) EpiPen auto-injector and announced that it would sell the emergency allergy therapy for $300 – the same price as Mylan’s own generic EpiPen product. The price for Teva’s product inspired some head-scratching among patient advocates and healthcare professionals. After all, when the FDA first approved […]
